TY - JOUR
T1 - Obstetric and neo-natal outcomes of ICSI cycles using pentoxifylline to identify viable spermatozoa in patients with immotile spermatozoa
AU - Navas, Purificación
AU - Paffoni, Alessio
AU - Intra, Giulia
AU - González-Utor, Antonio
AU - Clavero, Ana
AU - Gonzalvo, Maria Carmen
AU - Díaz, Rocío
AU - Peña, Rocío
AU - Restelli, Liliana
AU - Somigliana, Edgardo
AU - Papaleo, Enrico
AU - Castilla, Jose A.
AU - Viganò, Paola
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Pentoxifylline (PF) represents an effective tool in stimulating motility and identifying viable spermatozoa in intracytoplasmic sperm injection (ICSI) patients presenting exclusively with immotile spermatozoa. However, its use is not universally accepted for its possible detrimental effects on oocytes, embryos or newborns. To evaluate whether PF use may affect obstetrical/neo-natal outcomes, 102 patients achieving a clinical pregnancy after a PF-ICSI in four IVF units in Spain and Italy were followed up after delivery. Neo-natal malformations were classified according to the World Health Organization International Classification of Diseases (ICD-10, range Q00-Q99). Malformation rate was compared with data published by other groups regarding children conceived by conventional IVF or ICSI reporting a 5.3% and 4.4% frequency of ICD-10 codes, respectively. Of 134 clinical pregnancies, 122 babies (82 singletons and 40 twins) were registered. Among singletons, the rates of low birthweight (≤2500 g) and preterm birth (<37 weeks) were 6.1% and12%, respectively. Regarding malformation rate per live births, 4/122 (3.3%, 95% confidence interval: 0.9–8.2%) babies with ICD-10 malformations were recorded. This is the first report on neo-natal outcomes deriving from PF-ICSI. Although based on a limited cohort, results do not suggest an increase of adverse outcomes, including malformation rates, following this procedure.
AB - Pentoxifylline (PF) represents an effective tool in stimulating motility and identifying viable spermatozoa in intracytoplasmic sperm injection (ICSI) patients presenting exclusively with immotile spermatozoa. However, its use is not universally accepted for its possible detrimental effects on oocytes, embryos or newborns. To evaluate whether PF use may affect obstetrical/neo-natal outcomes, 102 patients achieving a clinical pregnancy after a PF-ICSI in four IVF units in Spain and Italy were followed up after delivery. Neo-natal malformations were classified according to the World Health Organization International Classification of Diseases (ICD-10, range Q00-Q99). Malformation rate was compared with data published by other groups regarding children conceived by conventional IVF or ICSI reporting a 5.3% and 4.4% frequency of ICD-10 codes, respectively. Of 134 clinical pregnancies, 122 babies (82 singletons and 40 twins) were registered. Among singletons, the rates of low birthweight (≤2500 g) and preterm birth (<37 weeks) were 6.1% and12%, respectively. Regarding malformation rate per live births, 4/122 (3.3%, 95% confidence interval: 0.9–8.2%) babies with ICD-10 malformations were recorded. This is the first report on neo-natal outcomes deriving from PF-ICSI. Although based on a limited cohort, results do not suggest an increase of adverse outcomes, including malformation rates, following this procedure.
KW - ICSI
KW - IVF
KW - Low birthweight
KW - Malformations
KW - Pentoxifylline
KW - Preterm birth
UR - http://www.scopus.com/inward/record.url?scp=85011418879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011418879&partnerID=8YFLogxK
U2 - 10.1016/j.rbmo.2017.01.009
DO - 10.1016/j.rbmo.2017.01.009
M3 - Article
AN - SCOPUS:85011418879
SN - 1472-6483
VL - 34
SP - 414
EP - 421
JO - Reproductive BioMedicine Online
JF - Reproductive BioMedicine Online
IS - 4
ER -